Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapeutics

Background:

• Advanced head and neck squamous cell carcinoma (HNSCC) treatment is limited in low-income countries due to high costs.
• Metronomic chemotherapy (TMC) has previously shown survival benefits in HNSCC.
• Low-dose nivolumab shows potential efficacy in HNSCC treatment.

Purpose of the Study:

• To evaluate if adding low-dose nivolumab to TMC improves overall survival (OS) in advanced HNSCC.
• To establish an alternative standard of care for HNSCC patients with limited access to full-dose immunotherapy.

Main Methods:

• A randomized phase III superiority study was conducted.
• Patients with advanced HNSCC (ECOG 0-1) received either TMC alone or TMC with low-dose nivolumab (TMC-I).
• The primary endpoint was 1-year OS.

Main Results:

• The 1-year OS increased from 16.3% to 43.4% in the TMC-I arm (HR, 0.545; P = .0036).
• Median OS improved from 6.7 months (TMC) to 10.1 months (TMC-I) (P = .0052).
• Grade 3+ adverse events were similar between arms (50% vs. 46.1%).

Conclusions:

• The addition of low-dose nivolumab to TMC significantly improves OS in advanced HNSCC.
• This combination represents a potential alternative standard of care for HNSCC patients.
• This is the first randomized study demonstrating the benefit of low-dose nivolumab with metronomic chemotherapy.